Incentives built into the new Medicare Part D drug plan to increase the use of generic drugs are driving down program costs significantly, according to the results of a new study. Researchers at Verispan found that 55% of all prescriptions being filled by Medicare patients during the first 3 months of the new program were for generic drugs.
Teva Pharmaceuticals was the leading supplier of drugs for Medicare recipients enrolled in Part D. Four other generic manufacturersMylan Pharmaceuticals, Watson Pharmaceuticals Inc, IVAX Pharmaceuticals Inc, and Mallinckrodt Medicalalso ranked among the top 10, the researchers said.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs